MedPath

Walking the Isobole of Drug Interaction

Not Applicable
Completed
Conditions
Hemodynamic Instability
Disorder of Oxygen Transport
Interaction
Anesthesia
Interventions
Drug: Group A propofol + remifentanil
Drug: Group B propofol + remifentanil
Drug: Group C propofol + remifentanil
Drug: group D propofol + remifentanil
Registration Number
NCT02067936
Lead Sponsor
University Medical Center Groningen
Brief Summary

The investigators study whether four equipotent combinations of propofol and remifentanil (as predicted by interaction models for "tolerance of laryngoscopy") result in identical haemodynamic conditions, independent of their relative different balance between the concentration of propofol and remifentanil.

Detailed Description

In anesthesia, the synergistic interaction between hypnotics and opioids is applied daily to give adequate anesthesia and analgesia at significantly lower doses compared with the ones needed if only one drug was given to reach the same effect. A lot of research has been done to quantify these interactions with a focus on the desired effects (Tolerance of laryngoscopy, tolerance of shake and shout etc...), but the simultaneous interaction on the unwanted side effects is less well described. The response surface model of Bouillon et al. and other models predict combinations of propofol and remifentanil effect-site concentrations that lead to an equipotent desired effect. Due to the availability of the models, the anesthesiologists now could use the knowledge on interactions to target specific effects more accurately, using predefined equipotent combinations of drugs: for instance, a desirable 90% probability of tolerance of laryngoscopy (TOL90) in the population can be reached through either a high propofol/low remifentanil combination, but equally well through a low propofol-high remifentanil combination.

However, at this time it is not known whether some of the combinations of propofol and remifentanil have a favorable hemodynamic stability compared to other equipotent combinations. The researcher in this study want to determine whether equipotent combinations of remifentanil and propofol (all deliberately selected to evoke 90% probability of "tolerance to laryngoscopy"), result in different effects on the undesired side effects of anesthetics, such as hemodynamic instability (hypotension, changes in heart rate or cardiac output), decreases in cerebral or tissue oxygenation (both measured with near infrared spectroscopy).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
87
Inclusion Criteria
  • Written informed consent
  • General anesthesia required for the procedure
  • Age: 18 years and older
  • American Society of Anesthesiologists (ASA) physical status I to III
Exclusion Criteria
  • Refusal to participate in this study
  • Contra-indications for the use of propofol or remifentanil
  • BMI > 35 kg/m2
  • Central nervous system disorders (i.e. cerebrovascular accident, dementia, seizures, psychiatric disorders)
  • Relevant hepatic disease (Child B or higher)
  • Regular use of medication that affects the central nervous system (i.e. benzodiazepines, antidepressants, antipsychotics, antiepileptic drugs)
  • Use of alpha-agonists or beta-blockers
  • Overt signs of alcohol abuse
  • Use of preoperative benzodiazepines (on the day of the study)
  • Beta blockers eye drips
  • Overt signs of Drugs abuse

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group A propofol + remifentanilGroup A propofol + remifentanilPropofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
Group B propofol + remifentanilGroup B propofol + remifentanilPropofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
Group C propofol + remifentanilGroup C propofol + remifentanilpropofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
group D propofol + remifentanilgroup D propofol + remifentanilpropofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
Primary Outcome Measures
NameTimeMethod
Blood pressureFrom start drug till intubation which will take on average 15 minutes of measurement

Continuously stored on a laptop (systolic, diastolic and mean blood pressure over time) using a Philips Non Invasive Blood Pressure measurements every minute and a Nexfin monitor (continuous non invasive blood pressure measurement)

Secondary Outcome Measures
NameTimeMethod
Electro Encephalographic derived indices of anesthetic depthFrom start first drug till intubation, which will take on average 15 minutes of measurement

Bispectral index, Wavelet Transformation (WAV) index, Quantium Consciousness Index (qCON), Quantium Nociception Index (qNOX) to observe whether multiple electroencephalographic derived depth of anesthesia indices indicate the same equipotent effect in all 4 groups. All these measures are unitless values that range between 100 (for a fully responsive condition) and 0 (for a fully unresponsive condition). All these measures are extracted from the same frontal electroencephalogram but use different composite mathematical algorithms to translate the cortical state in numbers. We want to observe whether these composite algorithms measure consistent behavior between groups. This outcome is mainly ment as hypothesis generating for future research.

Heart rateFrom start first drug till intubation, which will take on average 15 minutes of measurement

Difference in median/mean heart rate to determine differences between 4 groups with ANOVA.

Cerebral and tissue oxygenationFrom start drug till intubation, which will take on average 15 minutes of measurement

Continuously stored oxygenation saturation measured in tissue and cerebral cortex as measured by Near Infrared Spectrum Analysis (Forsyth monitor) and Inspectra monitor. Comparing differences between 4 groups with ANOVA.

Probability of tolerance to laryngoscopyone minute before laryngoscopy till three minutes after

During pharmacological steady state of propofol/remifentanil, a laryngoscopy will be performed by one researcher and response or tolerance of the stimulus will be observed. A positive response will be defined as any somatic movement, swallowing or coughing during three minutes after laryngoscopy was applied. Also a increase in heart rate or systolic blood pressure of more than 20% from baseline values (one minute before laryngoscopy) will be defined as a positive response. Through PROBIT analysis we can plot the probability of response to laryngoscopy (%) as a function of respectively propofol or remifentanil drug concentrations.

Cardiac indexFrom start first drug till intubation, which will take on average 15 minutes of measurement

Non invasive estimation of Cardiac output and Cardiac index patterns through the Nexfin monitor. Determine the differences between groups through ANOVA.

Trial Locations

Locations (1)

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath